Follow us : Twitter LinkedIn
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
Client Login
Home > Publications > Search for a publication

Search a publication

Title of Intellectual Property
Patents
European and Unitary Patent
US Patent
Trademark
European Union trademark
International Trademark
Design
Domain names
Software
Copyright
Theme
Health
Medtech
Patentability of Biological Material
Arbitration and Mediation
Contracts
Infringement
Regulation, Labelling
Data
Wine and Spirits
Pharmacy
Well-known TM, Dilution, Use
Accelerated Examination
European patent
Immunotherapy
PACTE Law
Biodiversity
Brexit
Biomarkers
Author name

Search result

5 publications

CRISPR/Cas9: a nebula of patents

By Lucile VERNOUX and Nicolas BOUQUIN, French and European Patent Attorneys
VERNOUXBOUQUIN.PNG Discover an extract from the Immunowatch, a one-of-a-kind newsletter in the field of immunotherapy published by our partner Mabdesign, which contains an in-depth analysis on CRISPR/Cas9 patents, and its challenging licensing landscape, conducted by Lucile Vernoux and Nicolas Bouquin.
Published on: 18th Feb 2022

Antibodies defined by functional features: Beware of sufficiency of disclosure !

By Cécile PUECH, French & European Patent Attorney
C.PUECH.jpg While European case law has long since limited the cases in which an antibody can be claimed solely by functional features, U.S. case law has recently moved in the same direction. Following two decisions by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) involving Amgen and Sanofi, it could be argued that the U.S. case law has taken a more drastically limited view on claiming antibody functional features.
Published on: 13th Oct 2021

More revoked patents in the CRISPR/Cas9 saga: The plot thickens

By Lucile VERNOUX and Nicolas BOUQUIN, French & European Patent Attorneys
VERNOUXBOUQUIN.PNG It is getting increasingly difficult to keep track of all the developments of the patent battle around the CRISPR-Cas9 technology. In a new turn of the story, patent EP 3 241 902 owned by University of California has been revoked by an Opposition Division of the European Patent Office.
Published on: 14th Jul 2021

Patentability of Antibodies: The new version of European Guidelines finally contains a dedicated section!

By Cécile PUECH, French and European Patent Attorney
C.PUECH.jpg The new version of the Guidelines for Examination in the EPO, which came into force on March 1st, contains a new section that at last spells out the approach of the EPO concerning the examination of patent applications relating to antibodies.
Published on: 19th March 2021

Disruptive CAR-T therapy is driving a new wave of patenting challenges

By Raphaëlle GILLET and Nicolas BOUQUIN, French & European Patent Attorneys
BouquinGillet_Article.jpg Discover an extract from the Immunowatch, published by our partner Mabdesign, and which contains an article written by Raphaëlle GILLET and Nicolas BOUQUIN, about CAR-T therapy.
Published on: 4th Dec 2020